MediciNova Inc

NAS:MNOV (USA)  
$ 1.39 -0.01 (-0.71%) 03:09 PM EST
At Loss
P/B:
1.09
Market Cap:
$ 68.17M
Enterprise V:
$ 18.37M
Volume:
10.66K
Avg Vol (2M):
48.70K
Warning! GuruFocus detected 1 Severe warning sign with MNOV. Try a 7-Day Free Trial to check it out.
Also Trade In:
Volume:
10.66K
Market Cap $:
68.17M
At Loss
Avg Vol (2M):
48.70K
Enterprise Value $:
18.37M
PB Ratio:
1.09
Alerts Website SEC Filings Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

MediciNova Inc (NAS:MNOV) Stock News, Headlines & Updates

MediciNova Inc Stock News from GuruFocus

Total 150
  • 1
  • 2
  • 3
  • 4
Oct 10, 2023
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Marketwired • 6:00pm
Oct 04, 2023
MediciNova Receives Gene Therapy Milestone Payment
Marketwired • 6:00pm
Sep 27, 2023
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
Marketwired • 6:00pm
Aug 18, 2023
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
GlobeNewswire • 11:00pm
Aug 17, 2023
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
Marketwired • 6:00pm
Aug 16, 2023
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Marketwired • 6:00pm
Aug 15, 2023
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
Marketwired • 6:00pm
Aug 14, 2023
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Marketwired • 6:00pm
Jun 29, 2023
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
Marketwired • 5:00am
Feb 20, 2023
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
sperokesalga • 5:00pm
Feb 08, 2023
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
sperokesalga • 5:00pm
Jan 30, 2023
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
Stock market mentor • 5:00pm
Jan 12, 2023
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
Stock market mentor • 5:00pm
Jan 11, 2023
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
Stock market mentor • 9:00pm
Jan 10, 2023
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
Stock market mentor • 9:00pm
Jan 05, 2023
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
Stock market mentor • 5:00pm
Dec 06, 2022
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
Value_Insider • 5:00pm
Dec 05, 2022
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
Value_Insider • 5:00pm
Aug 16, 2022
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
PurpleRose • 6:00am
Aug 10, 2022
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
PurpleRose • 7:00pm
Jul 27, 2022
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
PurpleRose • 6:00am
Jul 26, 2022
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
PurpleRose • 6:00am
Jul 13, 2022
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
PurpleRose • 7:33pm
Jul 09, 2022
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
GuruFocusNews • 6:37pm
Jul 08, 2022
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
GuruFocusNews • 7:24am
Jul 02, 2022
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
GuruFocusNews • 6:34pm
Jun 29, 2022
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
GuruFocusNews • 6:36pm
Jun 22, 2022
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
GuruFocusNews • 6:28pm
Apr 21, 2022
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
GuruFocusNews • 6:00pm
Apr 20, 2022
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
GuruFocusNews • 6:00pm
Apr 13, 2022
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
GuruFocusNews • 10:00pm
Apr 11, 2022
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
GuruFocusNews • 6:00am
Apr 07, 2022
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
GuruFocusNews • 6:00pm
Mar 17, 2022
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
GuruFocusNews • 6:00am
Feb 28, 2022
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
GuruFocusNews • 6:00am
Feb 22, 2022
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
GuruFocusNews • 6:00am
Feb 01, 2022
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
GuruFocusNews • 6:00am
Jan 31, 2022
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
GuruFocusNews • 6:00am
Jan 27, 2022
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
GuruFocusNews • 6:00am
Jan 26, 2022
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe
GuruFocusNews • 6:00am
Total 150
  • 1
  • 2
  • 3
  • 4
Show
Entries

Headlines

Total 0
  • 1
No recent news
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.